Alterity Therapeutics Ltd (AU:ATH) — Market Cap & Net Worth
Market Cap & Net Worth: Alterity Therapeutics Ltd (ATH)
Alterity Therapeutics Ltd (AU:ATH) has a market capitalization of $108.75 Million (AU$153.70 Million) as of September 23, 2026. Listed on the AU stock exchange, this Australia-based company holds position #18980 globally and #600 in its home market, demonstrating a -6.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alterity Therapeutics Ltd's stock price AU$0.42 by its total outstanding shares 10875416329 (10.88 Billion). Also see Alterity Therapeutics Ltd asset portfolio for a full breakdown of the balance sheet.
Alterity Therapeutics Ltd Market Cap History: 2015 to 2026
Alterity Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows growth from $823.37 Million to $3.23 Billion (12.14% CAGR). Also see Alterity Therapeutics Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Alterity Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alterity Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Alterity Therapeutics Ltd (ATH) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
11.32x
Alterity Therapeutics Ltd's market cap is 11.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $353.97 Million | $142.66K | -$7.73 Million | 2481.28x | N/A |
| 2017 | $546.35 Million | $132.40K | -$7.54 Million | 4126.62x | N/A |
| 2018 | $253.94 Million | $201.17K | -$8.27 Million | 1262.27x | N/A |
| 2019 | $153.90 Million | $108.54K | -$11.96 Million | 1417.95x | N/A |
| 2020 | $238.55 Million | $17.12K | -$10.06 Million | 13933.79x | N/A |
| 2021 | $161.60 Million | $4.34 Million | -$15.31 Million | 37.24x | N/A |
| 2022 | $76.95 Million | $5.12 Million | -$12.85 Million | 15.02x | N/A |
| 2023 | $53.87 Million | $3.92 Million | -$13.81 Million | 13.75x | N/A |
| 2024 | $61.56 Million | $4.02 Million | -$19.12 Million | 15.32x | N/A |
| 2025 | $61.56 Million | $5.44 Million | -$12.15 Million | 11.32x | N/A |
Competitor Companies of ATH by Market Capitalization
Companies near Alterity Therapeutics Ltd in the global market cap rankings as of September 23, 2026. Review ATH intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Alterity Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Alterity Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Alterity Therapeutics Ltd's market cap moved from $823.37 Million to $ 3.23 Billion, with a yearly change of 12.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$3.23 Billion | +5150.00% |
| 2025 | AU$61.56 Million | 0.00% |
| 2024 | AU$61.56 Million | +14.29% |
| 2023 | AU$53.87 Million | -30.00% |
| 2022 | AU$76.95 Million | -52.38% |
| 2021 | AU$161.60 Million | -32.26% |
| 2020 | AU$238.55 Million | +55.00% |
| 2019 | AU$153.90 Million | -39.39% |
| 2018 | AU$253.94 Million | -53.52% |
| 2017 | AU$546.35 Million | +54.35% |
| 2016 | AU$353.97 Million | -57.01% |
| 2015 | AU$823.37 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Alterity Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.75 Million USD |
| MoneyControl | $108.75 Million USD |
| MarketWatch | $108.75 Million USD |
| marketcap.company | $108.75 Million USD |
| Reuters | $108.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more